GB9402203D0
(en)
*
|
1994-02-04 |
1994-03-30 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
GB9407386D0
(en)
|
1994-04-14 |
1994-06-08 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
GB9416600D0
(en)
*
|
1994-08-17 |
1994-10-12 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
JP3501289B2
(ja)
|
1995-09-07 |
2004-03-02 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
医薬処方
|
AT407701B
(de)
*
|
1996-08-12 |
2001-05-25 |
Biochemie Gmbh |
Zur direkttablettierung geeignete mischung, die als wesentliche komponenten amoxicillin-trihydrat und das kaliumsalz der clavulansäure enthält und verfahren zur herstellung dieser mischung
|
TWI225402B
(en)
|
1996-03-13 |
2004-12-21 |
Biochemie Gmbh |
Auxiliary-free agglomerates
|
FR2753904B1
(fr)
*
|
1996-10-01 |
1998-10-30 |
Gattefosse Ets Sa |
Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
|
IL119627A
(en)
|
1996-11-17 |
2002-03-10 |
Yissum Res Dev Co |
PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
|
CA2280857A1
(fr)
*
|
1997-02-14 |
1998-08-20 |
Smithkline Beecham Laboratoires Pharmaceutiques |
Formulations pharmaceutiques comprenant de l'amoxycilline et du clavulanate
|
DE19705538C1
(de)
*
|
1997-02-14 |
1998-08-27 |
Goedecke Ag |
Verfahren zur Trennung von Wirkstoffen in festen pharmazeutischen Zubereitungen
|
WO1999013864A2
(fr)
*
|
1997-09-19 |
1999-03-25 |
Shire Laboratories, Inc. |
Granule de solution solide
|
US6365196B1
(en)
*
|
1997-10-03 |
2002-04-02 |
Smithkline Beecham Corporation |
Controlled release solid dosage forms of lithium carbonate
|
WO1999025343A1
(fr)
*
|
1997-11-17 |
1999-05-27 |
Gist-Brocades B.V. |
Granules comprenant du clavulanate et un ou plusieurs excipients
|
CZ299283B6
(cs)
*
|
1997-12-22 |
2008-06-04 |
Euro-Celtique, S. A. |
Léková forma pro perorální podání
|
AP1224A
(en)
|
1998-03-19 |
2003-11-14 |
Bristol Myers Squibb Co |
Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
|
US7250176B1
(en)
|
1999-04-13 |
2007-07-31 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection
|
OA11926A
(en)
*
|
1999-04-13 |
2006-04-12 |
Beecham Pharmacueticals Pte Lt |
Novel method of treatment
|
US6294199B1
(en)
|
1999-04-13 |
2001-09-25 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising administering amoxycillin
|
US6878386B1
(en)
|
1999-04-13 |
2005-04-12 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
|
US6991807B2
(en)
|
2000-02-24 |
2006-01-31 |
Advancis Pharmaceutical, Corp. |
Antibiotic composition
|
US6632453B2
(en)
|
2000-02-24 |
2003-10-14 |
Advancis Pharmaceutical Corp. |
Ciprofoxacin-metronidazole antibiotic composition
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US6663891B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Erythromyacin antibiotic product, use and formulation thereof
|
US6669948B2
(en)
|
2000-02-24 |
2003-12-30 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6627222B2
(en)
|
2000-02-24 |
2003-09-30 |
Advancis Pharmaceutical Corp. |
Amoxicillin-dicloxacillin antibiotic composition
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6610328B2
(en)
|
2000-02-24 |
2003-08-26 |
Advancis Pharmaceutical Corp. |
Amoxicillin-clarithromycin antibiotic composition
|
US6663890B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Metronidazole antibiotic product, use and formulation thereof
|
US7025989B2
(en)
|
2000-02-24 |
2006-04-11 |
Advancis Pharmaceutical Corp. |
Multiple-delayed released antibiotic product, use and formulation thereof
|
US6667057B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Levofloxacin antibiotic product, use and formulation thereof
|
US6667042B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Fluroquinilone antibiotic product, use and formulation thereof
|
US6730320B2
(en)
|
2000-02-24 |
2004-05-04 |
Advancis Pharmaceutical Corp. |
Tetracycline antibiotic product, use and formulation thereof
|
CA2399856C
(fr)
*
|
2000-02-24 |
2009-01-27 |
Edward M. Rudnic |
Composition antibiotique dotee d'inhibiteurs
|
US6623758B2
(en)
|
2000-02-24 |
2003-09-23 |
Advancis Pharmaceutical Corp. |
Cephalosporin-metronidazole antibiotic composition
|
US6623757B2
(en)
|
2000-02-24 |
2003-09-23 |
Advancis Pharmaceutical Corp. |
Antibiotic composition
|
US6955821B2
(en)
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
US7985420B2
(en)
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US8012504B2
(en)
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US7838032B2
(en)
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
EP1330236A2
(fr)
|
2000-10-12 |
2003-07-30 |
Beecham Pharmaceuticals (Pte) Limited |
Nouvelle formulation
|
US6756057B2
(en)
|
2000-10-12 |
2004-06-29 |
Beecham Pharmaceuticals (Pte) Limited |
Amoxicillin and potassium clavulanate dosage form
|
US7157095B2
(en)
|
2000-10-13 |
2007-01-02 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release antifungal product, use and formulation thereof
|
US7105174B2
(en)
|
2000-10-13 |
2006-09-12 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-neoplastic product, use and formulation thereof
|
US7074417B2
(en)
|
2000-10-13 |
2006-07-11 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-viral product, use and formulation thereof
|
US6541014B2
(en)
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US20020197314A1
(en)
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
AT413015B
(de)
*
|
2001-04-12 |
2005-10-15 |
Sandoz Ag |
Tablette enthaltend das k-salz der 3-(2-hydroxyethyliden)-7-oxo-4-oxa-1- azabicyclo(3.2.0)heptan-2 carbonsäure in hydrophobisierter form
|
GB0209265D0
(en)
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
JP2006514672A
(ja)
*
|
2003-03-04 |
2006-05-11 |
ノストラム・ファーマスーティカルズ・インコーポレイテッド |
疎水性物質を徐放剤として含有する制御性放出製剤
|
WO2005016278A2
(fr)
|
2003-08-12 |
2005-02-24 |
Advancis Pharmaceuticals Corporation |
Antibiotique, utilisation et formulation associees
|
BRPI0417348A
(pt)
*
|
2003-12-04 |
2007-03-13 |
Pfizer Prod Inc |
processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
|
CN1889931A
(zh)
*
|
2003-12-04 |
2007-01-03 |
辉瑞产品公司 |
利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾-冻凝方法
|
AR050615A1
(es)
|
2004-08-27 |
2006-11-08 |
Novartis Ag |
Composiciones farmaceuticas para la administracion oral
|
CN101014578B
(zh)
|
2004-09-16 |
2011-01-19 |
安斯泰来制药有限公司 |
三唑衍生物或其盐
|
CN103153288B
(zh)
|
2010-07-09 |
2017-02-15 |
詹姆斯·特林卡·格林 |
用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
|
GB201420306D0
(en)
|
2014-11-14 |
2014-12-31 |
Bio Images Drug Delivery Ltd |
Compositions
|
GB201420311D0
(en)
|
2014-11-14 |
2014-12-31 |
Bio Images Drug Delivery Ltd |
Pharmaceutical processing
|
CA3001337C
(fr)
|
2015-10-09 |
2023-12-12 |
Reckitt Benckiser Llc |
Formulation pharmaceutique
|
EP3994154A1
(fr)
|
2019-07-05 |
2022-05-11 |
GlaxoSmithKline Intellectual Property (No.2) Limited |
Streptomyces clavuligerus
|